Artwork

Indhold leveret af BackTable LLC. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af BackTable LLC eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
Player FM - Podcast-app
Gå offline med appen Player FM !

Ep. 475 Bariatric Embolization for Obesity Management with Dr Cliff Weiss

45:40
 
Del
 

Manage episode 435164401 series 2658136
Indhold leveret af BackTable LLC. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af BackTable LLC eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

While GLP-1 agonists continue to gain popularity in the medical management of diabetes and obesity, Dr. Cliff Weiss is exploring bariatric arterial embolization (BAE) as an adjunctive therapy to help patients sustain weight loss. Dr. Weiss, the Director of IR Research at Johns Hopkins, joins the show to discuss the techniques and impacts of BAE for obesity treatment.

---

CHECK OUT OUR SPONSOR

Reflow Medical

https://www.reflowmedical.com/

---

SYNPOSIS

Dr. Weiss outlines his initial research interest in gastric embolization of the fundus to reduce ghrelin production. He began by studying the use of sclerosants for embolization but later shifted to using embolic spheres. BAE involves the targeted embolization of the left gastric artery, with or without the left gastroepiploic artery, using 300-500 micron embolic spheres. Dr. Weiss also employs a dilute mixture of spheres and a vasodilator to achieve distal arterial penetration.

He describes the role of BAE in conjunction with existing surgical and pharmaceutical treatments. According to his experience, patients undergoing BAE achieve maximum weight loss 6-9 months after the procedure and can maintain this weight when they follow up in a weight management clinic. Additionally, Dr. Weiss reviews data from BAE studies, including the BEAT Obesity Trial and the recent BEATLES Trial.

---

TIMESTAMPS

00:00 - Introduction

03:21 - Early Research and Development of BAE

07:39 - Potential Role of BAE in Obesity Treatment

16:03 - Procedure Details

25:28 - Post-Procedure Care and Patient Management

28:06 - Insights from the BEAT Obesity Trial

33:38 - BEATLES Trial

37:38 - Combination Therapy for Obesity

---

RESOURCES

BEAT Obesity Trial:

https://pubs.rsna.org/doi/full/10.1148/radiol.2019182354

LC Bead/Bead Block:

https://www.bostonscientific.com/en-US/products/embolization/lc-bead.html

EmboSpheres:

https://www.merit.com/product/embosphere-microspheres/

EMBIO Trial:

https://bmjopen.bmj.com/content/13/9/e072327

BEATLES Trial:

https://www.jvir.org/article/S1051-0443(23)01155-7/fulltext

  continue reading

509 episoder

Artwork
iconDel
 
Manage episode 435164401 series 2658136
Indhold leveret af BackTable LLC. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af BackTable LLC eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

While GLP-1 agonists continue to gain popularity in the medical management of diabetes and obesity, Dr. Cliff Weiss is exploring bariatric arterial embolization (BAE) as an adjunctive therapy to help patients sustain weight loss. Dr. Weiss, the Director of IR Research at Johns Hopkins, joins the show to discuss the techniques and impacts of BAE for obesity treatment.

---

CHECK OUT OUR SPONSOR

Reflow Medical

https://www.reflowmedical.com/

---

SYNPOSIS

Dr. Weiss outlines his initial research interest in gastric embolization of the fundus to reduce ghrelin production. He began by studying the use of sclerosants for embolization but later shifted to using embolic spheres. BAE involves the targeted embolization of the left gastric artery, with or without the left gastroepiploic artery, using 300-500 micron embolic spheres. Dr. Weiss also employs a dilute mixture of spheres and a vasodilator to achieve distal arterial penetration.

He describes the role of BAE in conjunction with existing surgical and pharmaceutical treatments. According to his experience, patients undergoing BAE achieve maximum weight loss 6-9 months after the procedure and can maintain this weight when they follow up in a weight management clinic. Additionally, Dr. Weiss reviews data from BAE studies, including the BEAT Obesity Trial and the recent BEATLES Trial.

---

TIMESTAMPS

00:00 - Introduction

03:21 - Early Research and Development of BAE

07:39 - Potential Role of BAE in Obesity Treatment

16:03 - Procedure Details

25:28 - Post-Procedure Care and Patient Management

28:06 - Insights from the BEAT Obesity Trial

33:38 - BEATLES Trial

37:38 - Combination Therapy for Obesity

---

RESOURCES

BEAT Obesity Trial:

https://pubs.rsna.org/doi/full/10.1148/radiol.2019182354

LC Bead/Bead Block:

https://www.bostonscientific.com/en-US/products/embolization/lc-bead.html

EmboSpheres:

https://www.merit.com/product/embosphere-microspheres/

EMBIO Trial:

https://bmjopen.bmj.com/content/13/9/e072327

BEATLES Trial:

https://www.jvir.org/article/S1051-0443(23)01155-7/fulltext

  continue reading

509 episoder

Alle episoder

×
 
Loading …

Velkommen til Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Hurtig referencevejledning